Trial Profile
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/or Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 26 Jun 2021 Results of final 2 year efficacy and safety presented at The International Liver Congress 2021
- 26 Jun 2021 Results of final week 96 (n=93) assessing efficacy and safety of tenofovir-alafenamide in virally suppressed chronic hepatitis B patients with moderate or severe renal impairment or end-stage renal disease on hemodialysis, presented at The International Liver Congress 2021.